Ongoing Clinical Studies in Bladder Cancer

Cretostimogene grenadenorepvec is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and and two Phase 3 studies in the U.S. and Canada in BCG unresponsive, Intermediate-Risk and MIBC. One study is actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.

TRIAL TITLE

TRIAL NUMBER
STAGE
STATUS
PUBLICATION
BOND-002

Phase 2 Study in BCG-unresponsive NMIBC

Phase 2, US only

Completed
BOND-003

Phase 3 Study in BCG-unresponsive NMIBC

Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)

Recruiting

CORE-001

Phase 2 Combo with Pembrolizumab

Phase 2, Global (US, South Korea)

Active, Not Recruiting
PIVOT-006

Phase 3 Study
Intermediate-Risk

Phase 3, US
and Canada

Recruiting

Phase 3 Study
Intermediate-Risk

Patients and Urologists interested in participating should contact:

JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.

Expanded Patient Access

How Patients can Access the on-going Studies

CG Oncology is currently focused on conducting clinical research that evaluates the safety and effectiveness of investigational cretostimogene grenadenorepvec (CG0070) in Non-Muscle Invasive Bladder Cancer (NMIBC). Our clinical trials program is the primary way for interested patients to access cretostimogene grenadenorepvec at this time. We encourage patients to speak with their healthcare providers about participating in a clinical trial and may also find information on our current clinical studies on on-going clinical trials.

As a general policy, CG Oncology does not anticipate providing investigational medicines to patients until our clinical data suggests that the therapy has provided evidence of safety and efficacy as defined by the U.S. Food and Drug Administration. As a result, CG Oncology believes the most appropriate way to access our investigational therapy is through participating in one of our clinical trials.